Multimodality molecular imaging of CD105 (Endoglin) expression

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 1, 2011, Pages 32-42

  Zhang, Yin ^a   Yang, Yunan ^a,b   Hong, Hao ^a   Cai, Weibo ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Anti angiogenic therapy; Cancer; CD105 (Endoglin); Molecular imaging; Monoclonal antibody (mAb); Positron emission tomography (PET); Singlephoton emission computed tomography (SPECT); Tumor angiogenesis

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOGENESIS INHIBITOR; ARSENIC DERIVATIVE; CARBON 11; CONTRAST MEDIUM; COPPER 64; CYTOTOXIC AGENT; ENDOGLIN; FLUORINE 18; GADOLINIUM; GADOLINIUM PENTETATE; GEMCITABINE; INDIUM 111; IODINE 125; ISOTOPE; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD105; PEPTIDE; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TECHNETIUM 99M; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; YTTRIUM 90; ZIRCONIUM DERIVATIVE;

ANTIBODY LABELING; CONTRAST ENHANCED ULTRASOUND; DRUG HALF LIFE; ECHOGRAPHY; FLUORESCENCE IMAGING; HUMAN; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NANOTECHNOLOGY; NEAR INFRARED FLUORESCENCE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR; TUMOR VASCULARIZATION;

EID: 79951704331     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
5. Nyberg P, Xie L and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-3979.
6. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
7. Cai W and Chen X. Anti-angiogenic cancer therapy based on integrin avb3 antagonism. Anti- Cancer Agents Med Chem 2006; 6: 407-428.
8. Gwyther SJ. New imaging techniques in cancer management. Ann Oncol 2005; 16 Suppl 2: ii63-ii70.
9. Rudin M and Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003; 2: 123-131.
10. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007; 48: 18N, 21N.
11. Massoud TF and Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-580.
12. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L and Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
13. Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwartz A, Gur E, Skornick Y and Schneebaum S. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 2003; 44: 1413-1420.
14. Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ and Cherry SR. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med 2006; 47: 1968-1976.
15. Cai W and Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci 2007; 12: 4267-4279.
16. Haubner R.Avb3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006; 33 Suppl 13: 54-63.
17. Cai W and Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007; 3: 1840-1854.
18. Cai W and Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49 Suppl 2: 113S-128S.
19. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin avb3 targeted radiotracers for tumor imaging. Mol Pharm 2006; 3: 472-487.
20. Cai W, Niu G and Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 2008; 14: 2943-2973.
21. Cai W, Rao J, Gambhir SS and Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006; 5: 2624-2633.
22. Hong H, Zhang Y, Sun J and Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009; 4: 399-413 (PMC2753977).
23. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB and Wendel DP. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-1537.
24. Fonsatti E, Nicolay HJ, Altomonte M, Covre A and Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19.
25. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.
26. Fonsatti E, Sigalotti L, Arslan P, Altomonte M and Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003; 3: 427-432.
27. Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A and Secord AA. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 469-474.
28. Takahashi N, Haba A, Matsuno F and Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61: 7846-7854.
29. Lee S, Mandic J and Van Vliet KJ. Chemomechanical mapping of ligand-receptor binding kinetics on cells. Proc Natl Acad Sci U S A 2007; 104: 9609-9614.
30. Bloch SH, Dayton PA and Ferrara KW. Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag 2004; 23:18-29.
31. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radiol 2006; 60: 324-330.
32. Jakobsen JA. Ultrasound contrast agents: clinical applications. Eur Radiol 2001; 11: 1329-1337.
33. Stride E and Saffari N. Microbubble ultrasound contrast agents: a review. Proc Inst Mech Eng [H] 2003; 217: 429-447.
34. Kaufmann BA and Lindner JR. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol 2007; 18: 11-16.
35. Korpanty G, Grayburn PA, Shohet RV and Brekken RA. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005; 31: 1279-1283.
36. Korpanty G, Carbon JG, Grayburn PA, Fleming JB and Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13: 323-330.
37. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 2010; 23: 1183-1192.
38. Shohet RV, Chen S, Zhou YT, Wang Z, Meidell RS, Unger RH and Grayburn PA. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000; 101: 2554-2556.
39. Pathak AP, Gimi B, Glunde K, Ackerstaff E, Artemov D and Bhujwalla ZM. Molecular and functional imaging of cancer: Advances in MRI and MRS. Methods Enzymol 2004; 386: 3-60.
40. de Roos A, Doornbos J, Baleriaux D, Bloem HL and Falke TH. Clinical applications of gadolinium- DTPA in MRI. Magn Reson Annu 1988; 113-145.
41. Thorek DL, Chen AK, Czupryna J and Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006; 34: 23-38.
42. Zhang D, Feng XY, Henning TD, Wen L, Lu WY, Pan H, Wu X and Zou LG. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur J Radiol 2009; 70: 180-189.
43. Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng 2006; 8: 1-33.
44. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R and Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008; 5: 763-775.
45. van Roessel P and Brand AH. Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. Nat Cell Biol 2002; 4: E15-20.
46. Cai W, Hsu AR, Li ZB and Chen X. Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett 2007; 2: 265-281.
47. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003; 7: 626-634.
48. Vag T, Schramm T, Kaiser WA and Hilger I. Proliferating and quiescent human umbilical vein endothelial cells (HUVECs): a potential in vitro model to evaluate contrast agents for molecular imaging of angiogenesis. Contrast Media Mol Imaging 2009; 4: 192-198.
49. Yang Y, Hong H, Zhang Y, Leigh BR and Cai W. In vivo near-infrared fluorescence imaging of CD105 expression. Mol Imaging Biol submitted.
50. Mansfield JR, Gossage KW, Hoyt CC and Levenson RM. Autofluorescence removal, multiplexing, and automated analysis methods for invivo fluorescence imaging. J Biomed Opt 2005; 10: 41207.
51. Ntziachristos V, Tung CH, Bremer C and Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002; 8: 757-760.
52. Montet X, Ntziachristos V, Grimm J and Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res 2005; 65: 6330-6336.
53. Peremans K, Cornelissen B, Van Den Bossche B, Audenaert K and Van de Wiele C. A review of small animal imaging planar and pinhole spect Gamma camera imaging. Vet Radiol Ultrasound 2005; 46: 162-170.
54. Bredow S, Lewin M, Hofmann B, Marecos E and Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36: 675-681.
55. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M and Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000; 6: 2037-2043.
56. Tabata M, Kondo M, Haruta Y and Seon BK. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999; 82: 737-742.
57. Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, Owens S, Al-Mowallad AF, O'Dwyer S and Kumar S. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004; 109: 436-441.
58. Berman DS, Kiat H, Van Train K, Friedman JD, Wang FP and Germano G. Dual-isotope myocardial perfusion SPECT with rest thallium-201 and stress Tc-99m sestamibi. Cardiol Clin 1994; 12: 261-270.
59. Phelps ME, Hoffman EJ, Mullani NA and Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975; 16: 210-224.
60. Wadas TJ, Wong EH, Weisman GR and Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007; 13: 3-16.
61. Mendelson DS, Gordon MS, Rosen LS, Hurwitz H, Wong MK, Adams BJ, Alvarez D, Seon BK, Theuer CP and Leigh BR. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J Clin Oncol 2010; 28: 15s.
62. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR and Cai W. Positron emission tomography imaging of CD105 expression during tumour angiogenesis. Eur J Nucl Med Mol Imaging submitted.
63. Cai W, Chen K, He L, Cao Q, Koong A and Chen X. Quantitative PET of EGFR expression in xenograft- bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34: 850-858.
64. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H and Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011; 8: 135-143.
65. Tsujie M, Uneda S, Tsai H and Seon BK. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 2006; 29: 1087-1094.
66. Lee SY, Hong YD, Felipe PM, Pyun MS and Choi SJ. Radiolabeling of monoclonal anti-CD105 with 177Lu for potential use in radioimmunotherapy. Appl Radiat Isot 2009; 67: 1366-1369.
67. Volkel T, Holig P, Merdan T, Muller R and Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004; 1663: 158-166.
68. Muller D, Trunk G, Sichelstiel A, Zettlitz KA, Quintanilla M and Kontermann RE. Murine endoglin- specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J Immunol Methods 2008; 339: 90-98.
69. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R and Kontermann RE. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3: 882-891.
70. Korn T, Muller R and Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin- positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27: 99-106.
71. Cai W, Chen K, Li ZB, Gambhir SS and Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007; 48: 1862-1870.
72. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, Gambhir SS and Chen X. Peptidelabeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006; 6: 669-676.
73. Lopez-Novoa JM and Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010; 299: H959-H974.